Daniel O Persky

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4063262/publications.pdf

Version: 2024-02-01

85 papers	2,199 citations	257450 24 h-index	233421 45 g-index
85 all docs	85 docs citations	85 times ranked	3418 citing authors

#	Article	IF	Citations
1	Phase II Study of Rituximab Plus Three Cycles of CHOP and Involved-Field Radiotherapy for Patients With Limited-Stage Aggressive B-Cell Lymphoma: Southwest Oncology Group Study 0014. Journal of Clinical Oncology, 2008, 26, 2258-2263.	1.6	247
2	Blocking â€œdon't eat meâ€•signal of CD47-SIRPÎ± in hematological malignancies, an in-depth review. Blood Reviews, 2018, 32, 480-489.	5.7	137
3	Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete Remission. Journal of Clinical Oncology, 2017, 35, 2260-2267.	1.6	132
4	Continued Risk of Relapse Independent of Treatment Modality in Limited-Stage Diffuse Large B-Cell Lymphoma: Final and Long-Term Analysis of Southwest Oncology Group Study S8736. Journal of Clinical Oncology, 2016, 34, 2997-3004.	1.6	97
5	Increased MYC gene copy number correlates with increased mRNA levels in diffuse large B-cell lymphoma. Haematologica, 2010, 95, 597-603.	3.5	87
6	A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108. Leukemia and Lymphoma, 2009, 50, 728-735.	1.3	84
7	Parsaclisib, a potent and highly selective PI3KÎ´ inhibitor, in patients with relapsed or refractory B-cell malignancies. Blood, 2019, 133, 1742-1752.	1.4	84
8	Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the <scp>BCL</scp>2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory <scp>CD</scp>20⁺ lymphoid malignancies. British Journal of Haematology, 2015, 170, 669-678.	2.5	80
9	Aurora inhibitor MLN8237 in combination with docetaxel enhances apoptosis and anti-tumor activity in mantle cell lymphoma. Biochemical Pharmacology, 2011, 81, 881-890.	4.4	79
10	Donor origin CAR T cells: graft versus malignancy effect without GVHD, a systematic review. Immunotherapy, 2017, 9, 123-130.	2.0	78
11	Positron Emission Tomographyâ€“Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup National Clinical Trials Network Study S1001. Journal of Clinical Oncology, 2020, 38, 3003-3011.	1.6	75
12	Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral Tâ€cell nonâ€Hodgkin lymphoma. Cancer, 2013, 119, 371-379.	4.1	74
13	Comorbidities predict inferior outcomes in chronic lymphocytic leukemia treated with ibrutinib. Cancer, 2018, 124, 3192-3200.	4.1	70
14	Histone deacetylase inhibitors activate <scp>CIITA</scp> and MHC class <scp>II</scp> antigen expression in diffuse large Bâ€cell lymphoma. Immunology, 2013, 140, 259-272.	4.4	67
15	Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone. Haematologica, 2012, 97, 937-942.	3.5	64
16	Aurora A Inhibitor (MLN8237) plus Vincristine plus Rituximab Is Synthetic Lethal and a Potential Curative Therapy in Aggressive B-cell Non-Hodgkin Lymphoma. Clinical Cancer Research, 2012, 18, 2210-2219.	7.0	51
17	AT9283, a novel aurora kinase inhibitor, suppresses tumor growth in aggressive Bâ€cell lymphomas. International Journal of Cancer, 2012, 130, 2997-3005.	5.1	47
18	Alisertib (MLN8237) an investigational agent suppresses Aurora A and B activity, inhibits proliferation, promotes endo-reduplication and induces apoptosis in T-NHL cell lines supporting its importance in PTCL treatment. Leukemia Research, 2013, 37, 434-439.	0.8	45

#	Article	IF	Citations
19	A phase I/II trial of vorinostat (SAHA) in combination with rituximabâ€CHOP in patients with newly diagnosed advanced stage diffuse large Bâ€cell lymphoma (DLBCL): SWOG S0806. American Journal of Hematology, 2018, 93, 486-493.	4.1	38
20	Follicular Lymphoma: Recent and Emerging Therapies, Treatment Strategies, and Remaining Unmet Needs. Oncologist, 2019, 24, e1236-e1250.	3.7	36
21	Alisertib Added to Rituximab and Vincristine Is Synthetic Lethal and Potentially Curative in Mice with Aggressive DLBCL Co-Overexpressing MYC and BCL2. PLoS ONE, 2014, 9, e95184.	2.5	35
22	A phase II study of belinostat (PXD101) in relapsed and refractory aggressive B-cell lymphomas: SWOG S0520. Leukemia and Lymphoma, 2016, 57, 2359-2369.	1.3	33
23	Checkpoint Blockade Treatment May Sensitize Hodgkin Lymphoma to Subsequent Therapy. Oncologist, 2020, 25, 878-885.	3.7	28
24	Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/Vincristine in Relapsed/Refractory Aggressive B-cell Lymphoma. Clinical Cancer Research, 2018, 24, 6150-6159.	7.0	27
25	Genetic polymorphisms in oxidative stressâ€related genes are associated with outcomes following treatment for aggressive Bâ€cell nonâ€Hodgkin lymphoma. American Journal of Hematology, 2014, 89, 639-645.	4.1	26
26	Anti-CD47 Antibody, CC-90002, in Combination with Rituximab in Subjects with Relapsed and/or Refractory Non-Hodgkin Lymphoma (R/R NHL). Blood, 2019, 134, 4089-4089.	1.4	26
27	The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Three-Factor Comorbidity Model. Clinical Cancer Research, 2021, 27, 4814-4824.	7.0	23
28	Phase 2 Trial of Alisertib (MLN8237), An Investigational, Potent Inhibitor of Aurora A Kinase (AAK), in Patients (pts) with Aggressive B- and T-Cell Non-Hodgkin Lymphoma (NHL). Blood, 2011, 118, 95-95.	1.4	23
29	Impact of histological grading on survival in the SWOG S0016 follicular lymphoma cohort. Haematologica, 2018, 103, e151-e153.	3.5	22
30	Comparison of the Accuracy of CT Volume Calculated by Circumscription to Prolate Ellipsoid Volume (Bidimensional Measurement Multiplied by Coronal Long Axis). Academic Radiology, 2009, 16, 181-186.	2.5	20
31	R-CHOP, radioimmunotherapy, and maintenance rituximab in untreated follicular lymphoma (SWOG) Tj ETQq1 1 0.784314 rgBT /Ove	4.6	20
32	Incorporating acalabrutinib, a selective nextâ€generation Bruton tyrosine kinase inhibitor, into clinical practice for the treatment of haematological malignancies. British Journal of Haematology, 2021, 193, 15-25.	2.5	20
33	Checkpoint blockade treatment sensitises relapsed/refractory nonâ€Hodgkin lymphoma to subsequent therapy. British Journal of Haematology, 2020, 191, 44-51.	2.5	19
34	Localized large cell lymphoma: is there any need for radiation therapy?. Current Opinion in Oncology, 2009, 21, 401-406.	2.4	18
35	Ibritumomab consolidation after 3 cycles of CHOP plus radiotherapy in high-risk limited-stage aggressive B-cell lymphoma: SWOG S0313. Blood, 2015, 125, 236-241.	1.4	17
36	Yttrium-90-Ibritumomab Tiuxetan (ZevalinÂ®) Radioimmunotherapy after Cytoreduction with ESHAP Chemotherapy in Patients with Relapsed Follicular Non-Hodgkin Lymphoma: Final Results of a Phase II Study. Oncology, 2018, 94, 274-280.	1.9	14

#	Article	IF	Citations
37	Survival trends in chronic lymphocytic leukemia across treatment eras: US SEER database analysis (1985â€“2017). Annals of Hematology, 2021, 100, 2501-2512.	1.8	13
38	PET-Directed Therapy for Patients with Limited-Stage Diffuse Large B-Cell Lymphoma - Results of Intergroup Nctn Study S1001. Blood, 2019, 134, 349-349.	1.4	13
39	Phase 2 Open-Label Study of Bortezomib, Cladribine, and Rituximab in Advanced, Newly Diagnosed, and Relapsed/Refractory Mantle-Cell and Indolent Lymphomas. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 58-64.	0.4	10
40	Resistance to histone deacetylase inhibitors confers hypersensitivity to oncolytic reovirus therapy. Blood Advances, 2020, 4, 5297-5310.	5.2	9
41	Outcomes of primary and secondary prophylaxis of chemotherapy-induced and febrile neutropenia in bendamustine plus rituximab regimens in patients with lymphoma and chronic lymphocytic leukemia: real-world, single-center experience. Supportive Care in Cancer, 2021, 29, 4867-4874.	2.2	8
42	A Rare Presentation ofIn SituMantle Cell Lymphoma and Follicular Lymphoma: A Case Report and Review of the Literature. Case Reports in Hematology, 2014, 2014, 1-7.	0.4	7
43	Impact of Treatment Beyond Progression with Immune Checkpoint Blockade in Hodgkin Lymphoma. Oncologist, 2020, 25, e993-e997.	3.7	7
44	Checkpoint Blockade Therapy May Sensitize Hodgkin Lymphoma to Subsequent Therapy. Blood, 2018, 132, 1626-1626.	1.4	7
45	Role of Maintenance Therapy after High-Dose Chemotherapy and Autologous Hematopoietic Cell Transplantation in Aggressive Lymphomas: A Systematic Review. Biology of Blood and Marrow Transplantation, 2016, 22, 1182-1196.	2.0	6
46	Aggressive Leukemic Non-Nodal Mantle Cell Lymphoma With P53 Gene Rearrangement/Mutation is Highly Responsive to Rituximab/Ibrutinib Combination Therapy. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e93-e97.	0.4	6
47	Entospletinib and obinutuzumab in patients with relapsed/refractory chronic lymphocytic leukemia and B-cell malignancies. Haematologica, 2021, 106, 2022-2025.	3.5	6
48	A Phase 2 Study of MT-3724 to Evaluate Safety, Pharmacodynamics and Efficacy of MT-3724 for the Treatment of Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Blood, 2019, 134, 5324-5324.	1.4	6
49	Phase 1 Study Of Investigational Agent MLN8237 (Alisertib) + Rituximab Â± Vincristine In Patients (Pts) With Relapsed/Refractory (Rel/Ref) Aggressive B-Cell Lymphomas. Blood, 2013, 122, 3027-3027.	1.4	6
50	Aberrant cytoplasmic expression of MHCII confers worse progression free survival in diffuse large B-cell lymphoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 470, 113-117.	2.8	5
51	A simplified prognostic index for chronic lymphocytic leukemia treated with ibrutinib: Results from a multicenter retrospective cohort study. Leukemia Research, 2020, 89, 106302.	0.8	5
52	Absolute Lymphocyte Count Recovery Predicts Superior Survival and Is Independent of the International Prognostic Index in Patients Treated with CHOP or R-CHOP Chemotherapy for Diffuse Large B Cell Lymphoma.. Blood, 2005, 106, 931-931.	1.4	5
53	Fc Gamma Receptor 3a Genotype Predicts Overall Survival for Follicular Lymphoma Patients Treated On Southwest Oncology Group Trials with Combined Monoclonal Antibody Plus Chemotherapy but Not Chemotherapy Alone.. Blood, 2009, 114, 111-111.	1.4	5
54	Same-day versus next-day pegfilgrastim or pegfilgrastim-cbqv in patients with lymphoma receiving CHOP-like chemotherapy. Future Oncology, 2021, 17, 3485-3497.	2.4	4

#	Article	IF	Citations
55	Hodgkin Lymphoma Mimicking Osteomyelitis. Case Reports in Oncology, 2017, 10, 542-547.	0.7	3
56	Limited-stage DLBCL: itâ€™s patient selection. Blood, 2018, 131, 155-156.	1.4	3
57	Targeting JAK/STAT Signaling Antagonizes Resistance to Oncolytic Reovirus Therapy Driven by Prior Infection with HTLV-1 in Models of T-Cell Lymphoma. Viruses, 2021, 13, 1406.	3.3	3
58	The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Novel Comorbidity Score Derived from a Large Multicenter Retrospective Cohort Study of Patients Treated with Ibrutinib and/or Chemo-Immunotherapy (CIT). Blood, 2019, 134, 4286-4286.	1.4	3
59	Lymphocyte Count Persistence and Early Recovery Predicts Superior Survival and Is Independent of the International Prognostic Index in Patients Treated with CHOP Chemotherapy for Diffuse Large B Cell Lymphoma.. Blood, 2004, 104, 3252-3252.	1.4	3
60	Monotherapy Activity with the First CD20-Targeted Immunotoxin, MT-3724, in Subjects with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL). Blood, 2019, 134, 4098-4098.	1.4	2
61	Safety and Efficacy of Engineered Toxin Body MT-3724 in Relapsed or Refractory B-cell Non-Hodgkin's Lymphomas and Diffuse Large B-cell Lymphoma. Cancer Research Communications, 2022, 2, 307-315.	1.7	2
62	Economic Evaluation for the US of Ibrutinib Versus Acalabrutinib for Patients with Relapsed or Refractory Mantle Cell Lymphoma. Blood, 2018, 132, 4829-4829.	1.4	1
63	SYK Inhibitor Entospletinib in Combination with Obinutuzumab Demonstrates Efficacy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL). Blood, 2019, 134, 4295-4295.	1.4	1
64	Yttrium-90-Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy After Cytoreduction With ESHAP Chemotherapy In Patients With Relapsed Follicular Non-Hodgkinâ€™s Lymphoma (NHL): Interim Results Of a Phase II Study. Blood, 2013, 122, 4404-4404.	1.4	1
65	The Utility of Consolidative Upfront High Dose Chemoradiotherapy and ASCT in Patients with Mantle Cell Lymphoma (MCL).. Blood, 2005, 106, 2072-2072.	1.4	1
66	Mitotic Spindle Assembly Inhibition Through Aurora A (MLN8237) Plus Vincristine Is Synthetic Lethal and Synergizes with Rituximab As a Curative Therapy in Aggressive B-Cell Non-Hodgkin Lymphoma. Blood, 2011, 118, 2721-2721.	1.4	1
67	Efficacy of Same-Day Vs. Next-Day Pegfilgrastim for the Prevention of Chemotherapy-Induced (Febrile) Neutropenia (CIN/FN): A Meta-Analysis. Blood, 2015, 126, 4764-4764.	1.4	1
68	Oncolytic Reovirus Is an Effective Treatment for Histone Deacetylase Inhibitor Resistant T-Cell Lymphoma. Blood, 2018, 132, 2941-2941.	1.4	1
69	Outcomes of Primary and Secondary Prophylaxis of Chemotherapy Induced and Febrile Neutropenia (CIN/FN) in Bendamustine Plus Rituximab (BR) Regimens in Patients with Lymphoma and Chronic Lymphocytic Leukemia (CLL): Real-World, Single-Center Experience. Blood, 2019, 134, 5353-5353.	1.4	1
70	Cost-effectiveness and value of information analyses of Brutonâ€™s tyrosine kinase inhibitors in the treatment of relapsed or refractory mantle cell lymphoma in the United States. Journal of Managed Care & Specialty Pharmacy, 2022, 28, 390-400.	0.9	1
71	High Dose Chemoradiotherapy and ASCT Can Overcome the Prognostic Importance of Bcl-2, Bim, and p53 in Relapsed/Refractory Hodgkinâ€™s Lymphoma.. Blood, 2005, 106, 2073-2073.	1.4	0
72	Rituximab Maintenance Following High Dose Therapy and Autologous Stem Cell Rescue after RICE Cytoreduction Improves Event Free and Overall Survival. Blood, 2007, 110, 1280-1280.	1.4	0

#	Article	IF	Citations
73	Pentostatin and Alemtuzumab: An Immunosuppressive Nonmyeloablative Preparative Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation (PBSCT).. Blood, 2009, 114, 4312-4312.	1.4	0
74	Genetic Polymorphisms In Oxidative Stress-Related Genes Correlated with Outcome Following Anthracycline-Based Therapy for Aggressive B-Cell Non-Hodgkin Lymphomas. Blood, 2010, 116, 321-321.	1.4	0
75	Long Term Follow up of SWOG S0313: Ibritumomab Tiuxetan Consolidation after 3 Cycles of CHOP Plus Radiotherapy for High Risk Limited Stage Aggressive B-Cell Lymphoma. Blood, 2014, 124, 4414-4414.	1.4	0
76	Potent Efficacy of BCL2 Inhibition with ABT-199 in High-Risk Aggressive B-Lymphoma Models When Combined with Knockdown of MCL1. Blood, 2014, 124, 506-506.	1.4	0
77	Sequential RCHOP, Radioimmunotherapy and Rituximab Maintenance Improves Early Outcomes in Advanced Stage Follicular Lymphoma: 5 Year Outcomes from SWOG 0801. Blood, 2016, 128, 614-614.	1.4	0
78	Medical Comorbidities Assessed By CIRS Negatively Impact Survival in the Era of Targeted Therapies in CLL: A Multicenter Retrospective Analysis. Blood, 2017, 130, 918-918.	1.4	0
79	Checkpoint Blockade Therapy May Sensitize Aggressive and Indolent Non-Hodgkin Lymphoma to Subsequent Therapy. Blood, 2018, 132, 93-93.	1.4	0
80	Impact of Individual Comorbidities on Treatment Outcomes in Chronic Lymphocytic Leukemia. Blood, 2018, 132, 4848-4848.	1.4	0
81	Reply to E. Hawkes et al. Journal of Clinical Oncology, 2020, 38, 4222-4223.	1.6	0
82	A Comparison of Same Day Versus Next Day Administration of Pegfilgrastim in Lymphoma Patients Receiving CHOP Chemotherapy. Blood, 2020, 136, 11-11.	1.4	0
83	Impact of Treatment Sequencing on Outcomes and Costs in Relapsed Follicular or Other Low Grade B-Cell Non-Hodgkin Lymphoma - Results of an Evidence-Based Budget Impact Model. Blood, 2020, 136, 14-15.	1.4	0
84	The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI) Predicts Survival and Tolerance of Ibrutinib Therapy in Patients with CLL: A Multicenter Retrospective Cohort Study. Blood, 2020, 136, 1-3.	1.4	0
85	Transitioning Select Chemotherapeutics to the Outpatient Setting Improves Care and Reduces Costs. Oncology Issues, 2021, 36, 56-64.	0.1	0